About this trial
Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomized phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localised prostate cancer.
Patient Profile
People aged 18 years or older with either very high-risk localised prostate cancer, or very high risk features with PSA persistence or rise within one year following radical prostatectomy, suitable for Radiotherapy.
Where’s this trial being run?
Beacon Hospital, Bon Secours Radiotherapy Cork in Partnership with UPMC Hillman Cancer Centre, St Luke’s Hospital, St Luke’s Radiation Oncology Network @ St James’s Hospital, St Luke’s Radiation Oncology Network @ St Luke’s Hospital, Tallaght University Hospital, University Hospital Galway, Mater Misericordiae University Hospital, and Mater Private Hospital
Can I join this study / trial?
The first step we recommend is to talk to your doctor or the cancer trials team at your hospital. You can find contact details for cancer trials research units in Ireland here.
It’s also a good idea to print this page and bring it with you to your appointment. It can help guide the conversation and remind you of what to ask. You may also want to talk to your family or friends about your options, as they can offer support as you make decisions.
For more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | DASL HiCaP |
|---|---|
| Number: | CTRIAL-IE 19-32 |
| Full Title: | Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomized phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localised prostate cancer. |
| Principal Investigator: | Prof Ray McDermott |
|---|---|
| Type: | Collaborative |
| Sponsor: | EU Sponsor- Cancer Trials Irelamd |
| Recruitment Started: |
Global: March 2021 Ireland: 7th July 2021 |
| Global Recruitment Target: | 1100 |
|---|---|
| Ireland Recruitment Target: | 45 |